Strategies for immortalization of primary hepatocytes

Journal of Hepatology

Volumn 61, Issue 4, 2014, Pages 925-943

  Ramboer, Eva ^a   De Craene, Bram ^b,c   De Kock, Joery ^a   Vanhaecke, Tamara ^a   Berx, Geert ^b,c   Rogiers, Vera ^a   Vinken, Mathieu ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

Hepatocyte; Immortalization; Proliferation; Senescence

Indexed keywords

CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL GROWTH; CELL IMMORTALIZATION; CELL PROLIFERATION; GENE OVEREXPRESSION; HUMAN; IN VITRO STUDY; LIVER CELL; LIVER REGENERATION; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SENESCENCE; ANIMAL; CELL AGING; CELL CULTURE; CLASSIFICATION; CULTURE TECHNIQUE; CYTOLOGY; PATHOLOGY; PHYSIOLOGY; PROCEDURES;

ANIMALS; CELL AGING; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CELLS, CULTURED; HEPATOCYTES; HUMANS;

EID: 84926388302     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.05.046     Document Type: Review

References (180)

1. Pan XP, Li LJ. Advances in cell sources of hepatocytes for bioartificial liver. Hepatobiliary Pancreat Dis Int 2012; 11: 594-605.
2. Wege H, Le HT, Chui MS, Liu L, Wu J, Giri R, et al. Telomerase reconstitution immortalizes human fetal hepatocytes without disrupting their differentiation potential. Gastroenterology 2003; 124: 432-444.
3. Gómez-Lechón MJ, Donato MT, Castell JV, Jover R. Human hepatocytes in primary culture: the choice to investigate drug metabolism in man. Curr Drug Metab 2004; 5: 443-462.
4. Hewitt NJ, Lechón MJ, Houston JB, Hallifax D, Brown HS, Maurel P, et al. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 2007; 39: 159-234.
5. Allen JW, Bhatia SN. Improving the next generation of bioartificial liver devices. Semin Cell Dev Biol 2002; 13: 447-454.
6. Chamuleau RA, Deurholt T, Hoekstra R. Which are the right cells to be used in a bioartificial liver? Metab Brain Dis 2005; 20: 327-335.
7. Deurholt T, van Til NP, Chhatta AA, ten Bloemendaal L, Schwartlander R, Payne C, et al. Novel immortalized human fetal liver cell line, cBAL111, has the potential to differentiate into functional hepatocytes. BMC Biotechnol 2009; 9: 89.
8. Hoekstra R, Chamuleau RA. Recent developments on human cell lines for the bioartificial liver. Int J Artif Organs 2002; 25: 182-191.
9. Reid Y, Gaddipati JP, Yadav D, Kantor J. Establishment of a human neonatal hepatocyte cell line. In Vitro Cell Dev Biol Anim 2009; 45: 535-542.
10. Lipps C, May T, Hauser H, Wirth D. Eternity and functionality - rational access to physiologically relevant cell lines. Biol Chem 2013; 394: 1637-1648.
11. Sinz M, Kim S. Stem cells, immortalized cells and primary cells in ADMET assays. Drug Discov Today 2006; 3: 79-85.
12. Brandon EF, Raap CD, Meijerman I, Beijnen JH, Schellens JH. An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol Appl Pharmacol 2003; 189: 233-246.
13. Choi S, Sainz B, Corcoran P, Uprichard S, Jeong H. Characterization of increased drug metabolism activity in dimethyl sulfoxide (DMSO)-treated Huh7 hepatoma cells. Xenobiotica 2009; 39: 205-217.
14. Lim PL, Tan W, Latchoumycandane C, Mok WC, Khoo YM, Lee HS, et al. Molecular and functional characterization of drug-metabolizing enzymes and transporter expression in the novel spontaneously immortalized human hepatocyte line HC-04. Toxicol In Vitro 2007; 21: 1390-1401.
15. Szabo M, Veres Z, Baranyai Z, Jakab F, Jemnitz K. Comparison of human hepatoma HepaRG cells with human and rat hepatocytes in uptake transport assays in order to predict a risk of drug induced hepatotoxicity. PLoS One 2013; 8: e59432.
16. Aninat C, Piton A, Glaise D, Le Charpentier T, Langouët S, Morel F, et al. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 2006; 34: 75-83.
17. Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F, Guguen-Guillouzo C. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem Biol Interact 2007; 168: 66-73.
18. Marion MJ, Hantz O, Durantel D. The HepaRG cell line: biological properties and relevance as a tool for cell biology, drug metabolism, and virology studies. Methods Mol Biol 2010; 640: 261-272.
19. Clayton RF, Rinaldi A, Kandyba EE, Edward M, Willberg C, Klenerman P, et al. Liver cell lines for the study of hepatocyte functions and immunological response. Liver Int 2005; 25: 389-402.
20. Tsuruga Y, Kiyono T, Matsushita M, Takahashi T, Kasai H, Matsumoto S, et al. Establishment of immortalized human hepatocytes by introduction of HPV16 E6/E7 and hTERT as cell sources for liver cell-based therapy. Cell Transplant 2008; 17: 1083-1094.
21. Fukaya K, Asahi S, Nagamori S, Sakaguchi M, Gao C, Miyazaki M, et al. Establishment of a human hepatocyte line (OUMS-29) having CYP 1A1 and 1A2 activities from fetal liver tissue by transfection of SV40 LT. In Vitro Cell Dev Biol Anim 2001; 37: 266-269.
22. Hariparsad N, Carr BA, Evers R, Chu X. Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction. Drug Metab Dispos 2008; 36: 1046-1055.
23. Nguyen TH, Mai G, Villiger P, Oberholzer J, Salmon P, Morel P, et al. Treatment of acetaminophen-induced acute liver failure in the mouse with conditionally immortalized human hepatocytes. J Hepatol 2005; 43: 1031-1037.
24. Watanabe N, Odagiri H, Totsuka E, Sasaki M. A new method to immortalize primary cultured rat hepatocytes. Transplant Proc 2004; 36: 2457-2461.
25. Woodworth CD, Isom HC. Transformation of differentiated rat hepatocytes with adenovirus and adenovirus DNA. J Virol 1987; 61: 3570-3579.
26. Mangnall D, Bird NC, Majeed AW. The molecular physiology of liver regeneration following partial hepatectomy. Liver Int 2003; 23: 124-138.
27. Malato Y, Naqvi S, Schürmann N, Ng R, Wang B, Zape J, et al. Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. J Clin Invest 2011; 121: 4850-4860.
28. Corlu A, Loyer P. Regulation of the g1/s transition in hepatocytes: involvement of the cyclin-dependent kinase cdk1 in the DNA replication. Int J Hepatol 2012; 2012: 689324.
29. Fausto N, Campbell JS, Riehle KJ. Liver regeneration. Hepatology 2006; 43: S45-S53.
30. Taub R. Liver regeneration: from myth to mechanism. Nat Rev Mol Cell Biol 2004; 5: 836-847.
31. Fausto N. Liver regeneration. J Hepatol 2000; 32: 19-31.
32. Loyer P, Cariou S, Glaise D, Bilodeau M, Baffet G, Guguen-Guillouzo C. Growth factor dependence of progression through G1 and S phases of adult rat hepatocytes in vitro. Evidence of a mitogen restriction point in mid-late G1. J Biol Chem 1996; 271: 11484-11492.
33. Etienne PL, Baffet G, Desvergne B, Boisnard-Rissel M, Glaise D, Guguen- Guillouzo C. Transient expression of c-fos and constant expression of c-myc in freshly isolated and cultured normal adult rat hepatocytes. Oncogene Res 1988; 3: 255-262.
34. Paine AJ, Andreakos E. Activation of signalling pathways during hepatocyte isolation: relevance to toxicology in vitro. Toxicol In Vitro 2004; 18: 187-193.
35. Liu ML, Mars WM, Zarnegar R, Michalopoulos GK. Collagenase pretreatment and the mitogenic effects of hepatocyte growth factor and trans- forming growth factor-alpha in adult rat liver. Hepatology 1994; 19: 1521-1527.
36. Ilyin G, Rescan C, Rialland M, Loyer P, Baffet G, Guguen-Guillouzo C. Growth control and cell cycle progression in cultured hepatocytes. In: Berry M, Edwards A, editors. The Hepatocyte Review. Netherlands: Springer; 2000. p. 263-280.
37. Mayhew CN, Bosco EE, Fox SR, Okaya T, Tarapore P, Schwemberger SJ, et al. Liver-specific pRB loss results in ectopic cell cycle entry and aberrant ploidy. Cancer Res 2005; 65: 4568-4577.
38. Novák B, Tyson JJ. A model for restriction point control of the mammalian cell cycle. J Theor Biol 2004; 230: 563-579.
39. Schafer KA. The cell cycle: a review. Vet Pathol 1998; 35: 461-478.
40. Talarmin H, Rescan C, Cariou S, Glaise D, Zanninelli G, Bilodeau M, et al. The mitogen-activated protein kinase kinase/extracellular signal-regulated kinase cascade activation is a key signalling pathway involved in the regulation of G(1) phase progression in proliferating hepatocytes. Mol Cell Biol 1999; 19: 6003-6011.
41. Corlu A, Ilyin G, Cariou S, Lamy I, Loyer P, Guguen-Guillouzo C. The coculture: a system for studying the regulation of liver differentiation/ proliferation activity and its control. Cell Biol Toxicol 1997; 13: 235-242.
42. Albrecht JH, Mullany LK. Cell cycle control in the liver. In: Arias I, editor. The liver: biology and pathobiology. Chichester, UK: John Wiley & Sons; 2009. p. 1015-1027.
43. Nelsen CJ, Rickheim DG, Timchenko NA, Stanley MW, Albrecht JH. Transient expression of cyclin D1 is sufficient to promote hepatocyte replication and liver growth in vivo. Cancer Res 2001; 61: 8564-8568.
44. Rickheim DG, Nelsen CJ, Fassett JT, Timchenko NA, Hansen LK, Albrecht JH. Differential regulation of cyclins D1 and D3 in hepatocyte proliferation. Hepatology 2002; 36: 30-38.
45. Albrecht JH, Hansen LK. Cyclin D1 promotes mitogen-independent cell cycle progression in hepatocytes. Cell Growth Differ 1999; 10: 397-404.
46. Mullany LK, White P, Hanse EA, Nelsen CJ, Goggin MM, Mullany JE, et al. Distinct proliferative and transcriptional effects of the D-type cyclins in vivo. Cell Cycle 2008; 7: 2215-2224.
47. Wierød L, Rosseland CM, Lindeman B, Oksvold MP, Grøsvik H, Skarpen E, et al. CDK2 regulation through PI3K and CDK4 is necessary for cell cycle progression of primary rat hepatocytes. Cell Prolif 2007; 40: 475-487.
48. Boylan JM, Gruppuso PA. D-type cyclins and G1 progression during liver development in the rat. Biochem Biophys Res Commun 2005; 330: 722-730.
49. Curran TR, Bahner RI, Oh W, Gruppuso PA. Mitogen-independent DNA synthesis by fetal rat hepatocytes in primary culture. Exp Cell Res 1993; 209: 53-57.
50. Riehle KJ, Dan YY, Campbell JS, Fausto N. New concepts in liver regeneration. J Gastroenterol Hepatol 2011; 26: 203-212.
51. Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci 2005; 30: 630-641.
52. Malumbres M, Harlow E, Hunt T, Hunter T, Lahti JM, Manning G, et al. Cyclin-dependent kinases: a family portrait. Nat Cell Biol 2009; 11: 1275-1276.
53. Guo Y, Yang K, Harwalkar J, Nye JM, Mason DR, Garrett MD, et al. Phosphorylation of cyclin D1 at Thr 286 during S phase leads to its proteasomal degradation and allows efficient DNA synthesis. Oncogene 2005; 24: 2599-2612.
54. Chauhan A, Lorenzen S, Herzel H, Bernard S. Regulation of mammalian cell cycle progression in the regenerating liver. J Theor Biol 2011; 283: 103-112.
55. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003; 36: 131-149.
56. Fausto N, Campbell JS, Riehle KJ. Liver regeneration. J Hepatol 2012; 57: 692-694.
57. Michalopoulos GK. Liver regeneration. J Cell Physiol 2007; 213: 286-300.
58. Michalopoulos GK. Liver regeneration after partial hepatectomy: critical analysis of mechanistic dilemmas. Am J Pathol 2010; 176: 2-13.
59. Oe S, Lemmer ER, Conner EA, Factor VM, Levéen P, Larsson J, et al. Intact signaling by transforming growth factor beta is not required for termination of liver regeneration in mice. Hepatology 2004; 40: 1098-1105.
60. Wiemann SU, Satyanarayana A, Tsahuridu M, Tillmann HL, Zender L, Klempnauer J, et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J 2002; 16: 935-942.
61. Azuma H, Paulk N, Ranade A, Dorrell C, Al-Dhalimy M, Ellis E, et al. Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol 2007; 25: 903-910.
62. Chiu CP, Harley CB. Replicative senescence and cell immortality: the role of telomeres and telomerase. Proc Soc Exp Biol Med 1997; 214: 99-106.
63. Ozturk M, Arslan-Ergul A, Bagislar S, Senturk S, Yuzugullu H. Senescence and immortality in hepatocellular carcinoma. Cancer Lett 2009; 286: 103-113.
64. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965; 37: 614-636.
65. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. The essence of senescence. Genes Dev 2010; 24: 2463-2479.
66. Lee KM, Choi KH, Ouellette MM. Use of exogenous hTERT to immortalize primary human cells. Cytotechnology 2004; 45: 33-38.
67. Zhu J, Wang H, Bishop JM, Blackburn EH. Telomerase extends the lifespan of virus-transformed human cells without net telomere lengthening. Proc Natl Acad Sci U S A 1999; 96: 3723-3728.
68. Cascio SM. Novel strategies for immortalization of human hepatocytes. Artif Organs 2001; 25: 529-538.
69. Gorbunova V, Seluanov A. Coevolution of telomerase activity and body mass in mammals: from mice to beavers. Mech Ageing Dev 2009; 130: 3-9.
70. Nozawa K, Kurumiya Y, Yamamoto A, Isobe Y, Suzuki M, Yoshida S. Upregulation of telomerase in primary cultured rat hepatocytes. J Biochem 1999; 126: 361-367.
71. Yamaguchi Y, Nozawa K, Savoysky E, Hayakawa N, Nimura Y, Yoshida S. Change in telomerase activity of rat organs during growth and aging. Exp Cell Res 1998; 242: 120-127.
72. Inui T, Shinomiya N, Fukasawa M, Kobayashi M, Kuranaga N, Ohkura S, et al. Growth-related signaling regulates activation of telomerase in regenerating hepatocytes. Exp Cell Res 2002; 273: 147-156.
73. Overturf K, al-Dhalimy M, Ou CN, Finegold M, Grompe M. Serial transplantation reveals the stem-cell-like regenerative potential of adult mouse hepatocytes. Am J Pathol 1997; 151: 1273-1280.
74. Edwards A, Michalopoulos G. Conditions for growth of hepatocytes in culture. In: Berry M, Edwards A, editors. The Hepatocyte Review. Netherlands: Springer; 2000. p. 73-96.
75. Block GD, Locker J, Bowen WC, Petersen BE, Katyal S, Strom SC, et al. Population expansion, clonal growth, and specific differentiation patterns in primary cultures of hepatocytes induced by HGF/SF, EGF and TGF alpha in a chemically defined (HGM) medium. J Cell Biol 1996; 132: 1133-1149.
76. Runge DM, Runge D, Dorko K, Pisarov LA, Leckel K, Kostrubsky VE, et al. Epidermal growth factor- and hepatocyte growth factor-receptor activity in serum-free cultures of human hepatocytes. J Hepatol 1999; 30: 265-274.
77. Ohtani N, Yamakoshi K, Takahashi A, Hara E. The p16INK4a-RB pathway: molecular link between cellular senescence and tumor suppression. J Med Invest 2004; 51: 146-153.
78. Auer KL, Park JS, Seth P, Coffey RJ, Darlington G, Abo A, et al. Prolonged activation of the mitogen-activated protein kinase pathway promotes DNA synthesis in primary hepatocytes from p21Cip-1/WAF1-null mice, but not in hepatocytes from p16INK4a-null mice. Biochem J 1998; 336: 551-560.
79. Frémin C, Bessard A, Ezan F, Gailhouste L, Régeard M, Le Seyec J, et al. Multiple division cycles and long-term survival of hepatocytes are distinctly regulated by extracellular signal-regulated kinases ERK1 and ERK2. Hepatology 2009; 49: 930-939.
80. Harashima M, Seki T, Ariga T, Niimi S. Role of p16(INK4a) in the inhibition of DNA synthesis stimulated by HGF or EGF in primary cultured rat hepatocytes. Biomed Res 2013; 34: 269-273.
81. Ilyin GP, Glaise D, Gilot D, Baffet G, Guguen-Guillouzo C. Regulation and role of p21 and p27 cyclin-dependent kinase inhibitors during hepatocyte differentiation and growth. Am J Physiol Gastrointest Liver Physiol 2003; 285: G115-G127.
82. Tombes RM, Auer KL, Mikkelsen R, Valerie K, Wymann MP, Marshall CJ, et al. The mitogen-activated protein (MAP) kinase cascade can either stimulate or inhibit DNA synthesis in primary cultures of rat hepatocytes depending upon whether its activation is acute/phasic or chronic. Biochem J 1998; 330: 1451-1460.
83. Li J, Li LJ, Cao HC, Sheng GP, Yu HY, Xu W, et al. Establishment of highly differentiated immortalized human hepatocyte line with simian virus 40 large tumor antigen for liver based cell therapy. ASAIO J 2005; 51: 262-268.
84. Cai J, Ito M, Westerman KA, Kobayashi N, Leboulch P, Fox IJ. Construction of a non-tumorigenic rat hepatocyte cell line for transplantation: reversal of hepatocyte immortalization by site-specific excision of the SV40 T antigen. J Hepatol 2000; 33: 701-708.
85. Kobayashi N, Fujiwara T, Westerman KA, Inoue Y, Sakaguchi M, Noguchi H, et al. Prevention of acute liver failure in rats with reversibly immortalized human hepatocytes. Science 2000; 287: 1258-1262.
86. Mills JB, Rose KA, Sadagopan N, Sahi J, de Morais SM. Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. J Pharmacol Exp Ther 2004; 309: 303-309.
87. Zhao L, Li J, Lv G, Zhang A, Zhou P, Yang Y, et al. Evaluation of a reversibly immortalized human hepatocyte line in bioartificial liver in pigs. Afr J Biotechnol 2012; 11: 4116-4126.
88. Allen KJ, Reyes R, Demmler K, Mercer JF, Williamson R, Whitehead RH. Conditionally immortalized mouse hepatocytes for use in liver gene therapy. J Gastroenterol Hepatol 2000; 15: 1325-1332.
89. Bulera SJ, Haas MJ, Sattler CA, Li Y, Pitot HC. Cell lines with heterogeneous phenotypes result from a single isolation of albumin-sv40 T-antigen transgenic rat hepatocytes. Hepatology 1997; 25: 1192-1203.
90. Yanai N, Suzuki M, Obinata M. Hepatocyte cell lines established from transgenic mice harboring temperature-sensitive simian virus 40 large Tantigen gene. Exp Cell Res 1991; 197: 50-56.
91. McLean J. Immortalization strategies for mammalian cells. In: Jenkins N, editor. Animal cell biotechnology: methods and protocols. Humana Press; 1999. p. 61-72.
92. Noguchi H, Kobayashi N. Controlled expansion of mammalian cell populations by reversible immortalization. J Biotechnol Biomater 2013; 3: 158. http://dx.doi.org/10.4172/2155-952X.1000158.
93. Gabet AS, Accardi R, Bellopede A, Popp S, Boukamp P, Sylla BS, et al. Impairment of the telomere/telomerase system and genomic instability are associated with keratinocyte immortalization induced by the skin human papillomavirus type 38. FASEB J 2008; 22: 622-632.
94. Kyo S, Nakamura M, Kiyono T, Maida Y, Kanaya T, Tanaka M, et al. Successful immortalization of endometrial glandular cells with normal structural and functional characteristics. Am J Pathol 2003; 163: 2259-2269.
95. Caporossi D, Bacchetti S. Definition of adenovirus type 5 functions involved in the induction of chromosomal aberrations in human cells. J Gen Virol 1990; 71: 801-808.
96. Schramayr S, Caporossi D, Mak I, Jelinek T, Bacchetti S. Chromosomal damage induced by human adenovirus type 12 requires expression of the E1B 55-kilodalton viral protein. J Virol 1990; 64: 2090-2095.
97. Chang TH, Ray FA, Thompson DA, Schlegel R. Disregulation of mitotic checkpoints and regulatory proteins following acute expression of SV40 large T antigen in diploid human cells. Oncogene 1997; 14: 2383-2393.
98. Toouli CD, Huschtscha LI, Neumann AA, Noble JR, Colgin LM, Hukku B, et al. Comparison of human mammary epithelial cells immortalized by simian virus 40 T-Antigen or by the telomerase catalytic subunit. Oncogene 2002; 21: 128-139.
99. Stewart N, Bacchetti S. Expression of SV40 large T antigen, but not small t antigen, is required for the induction of chromosomal aberrations in transformed human cells. Virology 1991; 180: 49-57.
100. Ray FA, Peabody DS, Cooper JL, Cram LS, Kraemer PM. SV40 T antigen alone drives karyotype instability that precedes neoplastic transformation of human diploid fibroblasts. J Cell Biochem 1990; 42: 13-31.
101. Coursen JD, Bennett WP, Gollahon L, Shay JW, Harris CC. Genomic instability and telomerase activity in human bronchial epithelial cells during immortalization by human papillomavirus-16 E6 and E7 genes. Exp Cell Res 1997; 235: 245-253.
102. Kim BH, Sung SR, Choi EH, Kim YI, Kim KJ, Dong SH, et al. Dedifferentiation of conditionally immortalized hepatocytes with long-term in vitro passage. Exp Mol Med 2000; 32: 29-37.
103. Smalley M, Leiper K, Tootle R, McCloskey P, O'Hare MJ, Hodgson H. Immortalization of human hepatocytes by temperature-sensitive SV40 large-T antigen. In Vitro Cell Dev Biol Anim 2001; 37: 166-168.
104. Pfeifer AM, Cole KE, Smoot DT, Weston A, Groopman JD, Shields PG, et al. Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens. Proc Natl Acad Sci U S A 1993; 90: 5123-5127.
105. Woodworth CD, Kreider JW, Mengel L, Miller T, Meng YL, Isom HC. Tumorigenicity of simian virus 40-hepatocyte cell lines: effect of in vitro and in vivo passage on expression of liver-specific genes and oncogenes. Mol Cell Biol 1988; 8: 4492-4501.
106. Guha C, Chowdhury N, Chowdhury J. Reversibly immortalized human hepatocytes: an eternal fountain of liver support? Hepatology 2000; 32: 440-441.
107. Isom HC, Woodworth CD, Meng Y, Kreider J, Miller T, Mengel L. Introduction of the ras oncogene transforms a simian virus 40-immortalized hepatocyte cell line without loss of expression of albumin and other liverspecific genes. Cancer Res 1992; 52: 940-948.
108. Waki K, Anno K, Ono T, Ide T, Chayama K, Tahara H. Establishment of functional telomerase immortalized human hepatocytes and a hepatic stellate cell line for telomere-targeting anticancer drug development. Cancer Sci 2010; 101: 1678-1685.
109. Wege H, Chui MS, Le HT, Strom SC, Zern MA. In vitro expansion of human hepatocytes is restricted by telomere-dependent replicative aging. Cell Transplant 2003; 12: 897-906.
110. Okitsu T, Kobayashi N, Jun HS, Shin S, Kim SJ, Han J, et al. Transplantation of reversibly immortalized insulin-secreting human hepatocytes controls diabetes in pancreatectomized pigs. Diabetes 2004; 53: 105-112.
111. Totsugawa T, Yong C, Rivas-Carrillo JD, Soto-Gutierrez A, Navarro-Alvarez N, Noguchi H, et al. Survival of liver failure pigs by transplantation of reversibly immortalized human hepatocytes with Tamoxifen-mediated self-recombination. J Hepatol 2007; 47: 74-82.
112. Werner A, Duvar S, Müthing J, Büntemeyer H, Kahmann U, Lünsdorf H, et al. Cultivation and characterization of a new immortalized human hepatocyte cell line, HepZ, for use in an artificial liver support system. Ann N Y Acad Sci 1999; 875: 364-368.
113. Ray RB, Meyer K, Ray R. Hepatitis C virus core protein promotes immortalization of primary human hepatocytes. Virology 2000; 271: 197-204.
114. Basu A, Meyer K, Ray RB, Ray R. Hepatitis C virus core protein is necessary for the maintenance of immortalized human hepatocytes. Virology 2002; 298: 53-62.
115. Basu A, Meyer K, Lai KK, Saito K, Di Bisceglie AM, Grosso LE, et al. Microarray analyses and molecular profiling of Stat3 signaling pathway induced by hepatitis C virus core protein in human hepatocytes. Virology 2006; 349: 347-358.
116. Kunieda T, Kobayashi N, Sakaguchi M, Okitsu T, Totsugawa T, Watanabe T, et al. Transduction of immortalized human hepatocytes with p21 to enhance differentiated phenotypes. Cell Transplant 2002; 11: 421-428.
117. Kobayashi N, Kunieda T, Sakaguchi M, Okitsu T, Totsugawa T, Maruyama M, et al. Active expression of p21 facilitates differentiation of immortalized human hepatocytes. Transplant Proc 2003; 35: 433-434.
118. Fox IJ, Chowdhury NR, Gupta S, Kondapalli R, Schilsky ML, Stockert RJ, et al. Conditional immortalization of Gunn rat hepatocytes: an ex vivo model for evaluating methods for bilirubin-UDP-glucuronosyltransferase gene transfer. Hepatology 1995; 21: 837-846.
119. Schumacher IK, Okamoto T, Kim BH, Chowdhury NR, Chowdhury JR, Fox IJ. Transplantation of conditionally immortalized hepatocytes to treat hepatic encephalopathy. Hepatology 1996; 24: 337-343.
120. Zaret KS, DiPersio CM, Jackson DA, Montigny WJ, Weinstat DL. Conditional enhancement of liver-specific gene transcription. Proc Natl Acad Sci U S A 1988; 85: 9076-9080.
121. Watanabe T, Shibata N, Westerman KA, Okitsu T, Allain JE, Sakaguchi M, et al. Establishment of immortalized human hepatic stellate scavenger cells to develop bioartificial livers. Transplantation 2003; 75: 1873-1880.
122. Inoue Y, Miyazaki M, Tsuji T, Sakaguchi M, Fukaya K, Huh NH, et al. Reactivation of liver-specific gene expression in an immortalized human hepatocyte cell line by introduction of the human HNF4alpha2 gene. Int J Mol Med 2001; 8: 481-487.
123. Paillard F. Reversible cell immortalization with the Cre-lox system. Hum Gene Ther 1999; 10: 1597-1598.
124. Chen Y, Li J, Liu X, Zhao W, Wang Y, Wang X. Transplantation of immortalized human fetal hepatocytes prevents acute liver failure in 90% hepatectomized mice. Transplant Proc 2010; 42: 1907-1914.
125. Nakamura J, Okamoto T, Schumacher IK, Tabei I, Chowdhury NR, Chowdhury JR, et al. Treatment of surgically induced acute liver failure by transplantation of conditionally immortalized hepatocytes. Transplantation 1997; 63: 1541-1547.
126. Anastassiadis K, Rostovskaya M, Lubitz S, Weidlich S, Stewart AF. Precise conditional immortalization of mouse cells using tetracycline-regulated SV40 large T-antigen. Genesis 2010; 48: 220-232.
127. May T, Hauser H, Wirth D. Transcriptional control of SV40 T-antigen expression allows a complete reversion of immortalization. Nucleic Acids Res 2004; 32: 5529-5538.
128. Westerman KA, Leboulch P. Reversible immortalization of mammalian cells mediated by retroviral transfer and site-specific recombination. Proc Natl Acad Sci U S A 1996; 93: 8971-8976.
129. Ito M, Ito R, Yoshihara D, Ikeno M, Kamiya M, Suzuki N, et al. Immortalized hepatocytes using human artificial chromosome. Cell Transplant 2008; 17: 165-171.
130. Kobayashi N, Noguchi H, Fujiwara T, Tanaka N. Establishment of a reversibly immortalized human hepatocyte cell line by using Cre/loxP site-specific recombination. Transplant Proc 2000; 32: 1121-1122.
131. Jazwa A, Florczyk U, Jozkowicz A, Dulak J. Gene therapy on demand: site specific regulation of gene therapy. Gene 2013; 525: 229-238.
132. Wang X, Mani P, Sarkar DP, Roy-Chowdhury N, Roy-Chowdhury J. Ex vivo gene transfer into hepatocytes. Methods Mol Biol 2009; 481: 117-140.
133. Macdonald C, Willett B. The immortalisation of rat hepatocytes by transfection with SV40 sequences. Cytotechnology 1997; 23: 161-170.
134. Woodworth C, Secott T, Isom HC. Transformation of rat hepatocytes by transfection with simian virus 40 DNA to yield proliferating differentiated cells. Cancer Res 1986; 46: 4018-4026.
135. Schippers IJ, Moshage H, Roelofsen H, Müller M, Heymans HS, Ruiters M, et al. Immortalized human hepatocytes as a tool for the study of hepatocytic (de-) differentiation. Cell Biol Toxicol 1997; 13: 375-386.
136. Kobayashi N, Noguchi H, Watanabe T, Matsumura T, Totsugawa T, Fujiwara T, et al. Role of immortalized hepatocyte transplantation in acute liver failure. Transplant Proc 2001; 33: 645-646.
137. Noguchi M, Hirohashi S. Cell lines from non-neoplastic liver and hepatocellular carcinoma tissue from a single patient. In Vitro Cell Dev Biol Anim 1996; 32: 135-137.
138. Kazuki Y, Oshimura M. Human artificial chromosomes for gene delivery and the development of animal models. Mol Ther 2011; 19: 1591-1601.
139. Zahler MH, Irani A, Malhi H, Reutens AT, Albanese C, Bouzahzah B, et al. The application of a lentiviral vector for gene transfer in fetal human hepatocytes. J Gene Med 2000; 2: 186-193.
140. Kobayashi N, Noguchi H, Fujiwara T, Westerman KA, Leboulch P, Tanaka N. Establishment of a highly differentiated immortalized adult human hepatocyte cell line by retroviral gene transfer. Transplant Proc 2000; 32: 2368-2369.
141. Pan X, Li J, Du W, Yu X, Zhu C, Yu C, et al. Establishment and characterization of immortalized human hepatocyte cell line for applications in bioartificial livers. Biotechnol Lett 2012; 34: 2183-2190.
142. Nguyen TH, Oberholzer J, Birraux J, Majno P, Morel P, Trono D. Highly efficient lentiviral vector-mediated transduction of nondividing, fully reimplantable primary hepatocytes. Mol Ther 2002; 6: 199-209.
143. Ohashi K, Park F, Kay MA. Hepatocyte transplantation: clinical and experimental application. J Mol Med (Berl) 2001; 79: 617-630.
144. Selden C, Mellor N, Rees M, Laurson J, Kirwan M, Escors D, et al. Growth factors improve gene expression after lentiviral transduction in human adult and fetal hepatocytes. J Gene Med 2007; 9: 67-76.
145. Zamule SM, Strom SC, Omiecinski CJ. Preservation of hepatic phenotype in lentiviral-transduced primary human hepatocytes. Chem Biol Interact 2008; 173: 179-186.
146. Rothe M, Rittelmeyer I, Iken M, Rüdrich U, Schambach A, Glage S, et al. Epidermal growth factor improves lentivirus vector gene transfer into primary mouse hepatocytes. Gene Ther 2012; 19: 425-434.
147. Ito M, Ikeno M, Nagata H, Yamamoto T, Hiroguchi A, Fox IJ, et al. Treatment of nonalbumin rats by transplantation of immortalized hepatocytes using artificial human chromosome. Transplant Proc 2009; 41: 422-424.
148. Shitara S, Kakeda M, Nagata K, Hiratsuka M, Sano A, Osawa K, et al. Telomerase-mediated life-span extension of human primary fibroblasts by human artificial chromosome (HAC) vector. Biochem Biophys Res Commun 2008; 369: 807-811.
149. Cai J, Ito M, Nagata H, Westerman KA, Lafleur D, Chowdhury JR, et al. Treatment of liver failure in rats with end-stage cirrhosis by transplantation of immortalized hepatocytes. Hepatology 2002; 36: 386-394.
150. Tada K, Roy-Chowdhury N, Prasad V, Kim BH, Manchikalapudi P, Fox IJ, et al. Long-term amelioration of bilirubin glucuronidation defect in Gunn rats by transplanting genetically modified immortalized autologous hepatocytes. Cell Transplant 1998; 7: 607-616.
151. Kim BH, Han YS, Dong SH, Kim HJ, Chang YW, Lee JI, et al. Temporary amelioration of bilirubin conjugation defect in Gunn rats by transplanting conditionally immortalized hepatocytes. J Gastroenterol Hepatol 2002; 17: 690-696.
152. Kobayashi N, Noguchi H, Fujiwara T, Tanaka N. Xenotransplantation of immortalized human hepatocytes for experimental acute liver failure in rats. Transplant Proc 2000; 32: 1123-1124.
153. Tsuruga Y, Kiyono T, Matsushita M, Takahashi T, Kasai N, Matsumoto S, et al. Effect of intrasplenic transplantation of immortalized human hepatocytes in the treatment of acetaminophen-induced acute liver failure SCID mice. Transplant Proc 2008; 40: 617-619.
154. Poyck PP, van Wijk AC, van der Hoeven TV, de Waart DR, Chamuleau RA, van Gulik TM, et al. Evaluation of a new immortalized human fetal liver cell line (cBAL111) for application in bioartificial liver. J Hepatol 2008; 48: 266-275.
155. Werner A, Duvar S, Müthing J, Büntemeyer H, Lünsdorf H, Strauss M, et al. Cultivation of immortalized human hepatocytes HepZ on macroporous CultiSpher G microcarriers. Biotechnol Bioeng 2000; 68: 59-70.
156. Yu CB, Lv GL, Pan XP, Chen YS, Cao HC, Zhang YM, et al. In vitro large-scale cultivation and evaluation of microencapsulated immortalized human hepatocytes (HepLL) in roller bottles. Int J Artif Organs 2009; 32: 272-281.
157. Akiyama I, Tomiyama K, Sakaguchi M, Takaishi M, Mori M, Hosokawa M, et al. Expression of CYP3A4 by an immortalized human hepatocyte line in a three-dimensional culture using a radial-flow bioreactor. Int J Mol Med 2004; 14: 663-668.
158. Nibourg GA, Chamuleau RA, van Gulik TM, Hoekstra R. Proliferative human cell sources applied as biocomponent in bioartificial livers: a review. Expert Opin Biol Ther 2012; 12: 905-921.
159. Buzzelli MD, Nagarajan M, Radtka JF, Shumate ML, Navaratnarajah M, Lang CH, et al. Nuclear factor-kappaB mediates the inhibitory effects of tumor necrosis factor-alpha on growth hormone-inducible gene expression in liver. Endocrinology 2008; 149: 6378-6388.
160. Ahmed TA, Buzzelli MD, Lang CH, Capen JB, Shumate ML, Navaratnarajah M, et al. Interleukin-6 inhibits growth hormone-mediated gene expression in hepatocytes. Am J Physiol Gastrointest Liver Physiol 2007; 292: G1793-G1803.
161. Bai J, Li J, Mao Q. Construction of a single lentiviral vector containing tetracycline-inducible Alb-uPA for transduction of uPA expression in murine hepatocytes. PLoS One 2013; 8: e61412.
162. Samavati L, Lee I, Mathes I, Lottspeich F, Hüttemann M. Tumor necrosis factor alpha inhibits oxidative phosphorylation through tyrosine phosphorylation at subunit I of cytochrome c oxidase. J Biol Chem 2008; 283: 21134-21144.
163. Gao Y, Theng SS, Zhuo J, Teo WB, Ren J, Lee CG. FAT10, an ubiquitin-like protein, confers malignant properties in non-tumorigenic and tumorigenic cells. Carcinogenesis 2014; 35: 923-934.
164. Tomimaru Y, Xu CQ, Nambotin SB, Yan T, Wands JR, Kim M. Loss of exon 4 in a human T-cell factor-4 isoform promotes hepatic tumourigenicity. Liver Int 2013; 33: 1536-1548.
165. Rand AA, Rooney JP, Butt CM, Meyer JN, Mabury SA. Cellular toxicity associated with exposure to perfluorinated carboxylates (PFCAs) and their metabolic precursors. Chem Res Toxicol 2014; 27: 42-50.
166. Krajka-Kuźniak V, Paluszczak J, Baer-Dubowska W. Xanthohumol induces phase II enzymes via Nrf2 in human hepatocytes in vitro. Toxicol In Vitro 2013; 27: 149-156.
167. Raychoudhuri A, Shrivastava S, Steele R, Dash S, Kanda T, Ray R, et al. Hepatitis C virus infection impairs IRF-7 translocation and Alpha interferon synthesis in immortalized human hepatocytes. J Virol 2010; 84: 10991-10998.
168. Raychoudhuri A, Shrivastava S, Steele R, Kim H, Ray R, Ray RB. ISG56 and IFITM1 proteins inhibit hepatitis C virus replication. J Virol 2011; 85: 12881-12889.
169. Brown JJ, Parashar B, Moshage H, Tanaka KE, Engelhardt D, Rabbani E, et al. A long-term hepatitis B viremia model generated by transplanting nontumorigenic immortalized human hepatocytes in Rag-2-deficient mice. Hepatology 2000; 31: 173-181.
170. McGinnity DF, Zhang G, Kenny JR, Hamilton GA, Otmani S, Stams KR, et al. Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells. Drug Metab Dispos 2009; 37: 1259-1268.
171. Ramirez RD, Herbert BS, Vaughan MB, Zou Y, Gandia K, Morales CP, et al. Bypass of telomere-dependent replicative senescence (M1) upon overexpression of Cdk4 in normal human epithelial cells. Oncogene 2003; 22: 433-444.
172. Ramirez RD, Morales CP, Herbert BS, Rohde JM, Passons C, Shay JW, et al. Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions. Genes Dev 2001; 15: 398-403.
173. Shiomi K, Kiyono T, Okamura K, Uezumi M, Goto Y, Yasumoto S, et al. CDK4 and cyclin D1 allow human myogenic cells to recapture growth property without compromising differentiation potential. Gene Ther 2011; 18: 857-866.
174. Cooper G. The eukaryotic cell cycle. In: Cooper G, editor. The cell: a molecular approach. Sunderland (MA): Sinauer Associates; 2000.
175. Garnier D, Loyer P, Ribault C, Guguen-Guillouzo C, Corlu A. Cyclindependent kinase 1 plays a critical role in DNA replication control during rat liver regeneration. Hepatology 2009; 50: 1946-1956.
176. LeCluyse E, Sinz M, Hewitt N, Ferguson S, Jasminder S. Cytochrome P450 induction. In: Lu C, Li A, editors. Enzyme inhibition in drug discovery and development: the good and the bad. Wiley; 2010. p. 265-314.
177. Haker B, Fuchs S, Dierlamm J, Brümmendorf TH, Wege H. Absence of oncogenic transformation despite acquisition of cytogenetic aberrations in long-term cultured telomerase-immortalized human fetal hepatocytes. Cancer Lett 2007; 256: 120-127.
178. Woodworth CD, Isom HC. Regulation of albumin gene expression in a series of rat hepatocyte cell lines immortalized by simian virus 40 and maintained in chemically defined medium. Mol Cell Biol 1987; 7: 3740-3748.
179. Bayad J, Bagrel D, Sabolovic N, Magdalou J, Siest G. Expression and regulation of drug metabolizing enzymes in an immortalized rat hepatocyte cell line. Biochem Pharmacol 1991; 42: 1345-1351.
180. Kim BH, Sung SR, Park JK, Kim YI, Kim KJ, Dong SH, et al. Survival of conditionally immortalized hepatocytes in the spleen of syngeneic rats. J Gastroenterol Hepatol 2001; 16: 52-60.